Sysmex Corporation ADR (OTCMKTS:SSMXY - Get Free Report) saw a significant increase in short interest in March. As of March 13th, there was short interest totaling 87,678 shares, an increase of 111.6% from the February 26th total of 41,438 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 591,040 shares, the days-to-cover ratio is currently 0.1 days.
Sysmex Price Performance
OTCMKTS:SSMXY opened at $8.46 on Thursday. The firm has a market capitalization of $5.33 billion, a price-to-earnings ratio of 17.63 and a beta of 1.14. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.33 and a quick ratio of 2.44. The business has a 50 day simple moving average of $9.17 and a 200-day simple moving average of $10.30. Sysmex has a 1 year low of $8.15 and a 1 year high of $19.65.
Sysmex (OTCMKTS:SSMXY - Get Free Report) last released its earnings results on Thursday, February 12th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.01. Sysmex had a return on equity of 9.27% and a net margin of 8.86%.The firm had revenue of $837.32 million for the quarter, compared to the consensus estimate of $819.99 million. Equities analysts forecast that Sysmex will post 0.57 EPS for the current year.
Wall Street Analyst Weigh In
Separately, Citigroup cut shares of Sysmex from a "strong-buy" rating to a "hold" rating in a research note on Monday, March 16th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold".
View Our Latest Stock Report on SSMXY
Sysmex Company Profile
(
Get Free Report)
Sysmex Corporation OTCMKTS: SSMXY is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex's product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.
The company's core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sysmex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sysmex wasn't on the list.
While Sysmex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.